IBRX Poised for Russell 1000 Inclusion Amid Retail Trader Speculation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 54 minutes ago
0mins
Source: stocktwits
- Market Reconstitution Focus: Retail traders are closely watching Friday's Russell reconstitution, with IBRX potentially graduating from the Russell 2000 to the Russell 1000, as its current market cap of approximately $7.67 billion exceeds the $5.7 billion cutoff for 2026, which could trigger significant index fund buying if successful.
- Price Volatility Analysis: IBRX rose 1% in extended trading on Tuesday to close at $7.32, despite being down 3% so far this month; however, market optimism regarding its potential Russell 1000 inclusion suggests it could improve trading characteristics and attract more passive investors.
- Surge in Trading Volume: According to Stocktwits, IBRX's message volume surged by 349% over the past month, while retail sentiment shifted from 'bullish' to 'bearish', indicating heightened market attention and uncertainty surrounding the upcoming reconstitution.
- FDA Approval Boost: Last month, the FDA accepted ImmunityBio's application to expand Anktiva for bladder cancer treatment, with a decision expected on January 6, 2027, and clinical trial results showing 58.2% of patients disease-free after 12 months, further bolstering market confidence in IBRX.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.220
Low
5.00
Averages
7.33
High
9.00
Current: 7.220
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IBRX Poised for Russell 1000 Inclusion Amid Retail Trader Speculation
- Market Reconstitution Focus: Retail traders are closely watching Friday's Russell reconstitution, with IBRX potentially graduating from the Russell 2000 to the Russell 1000, as its current market cap of approximately $7.67 billion exceeds the $5.7 billion cutoff for 2026, which could trigger significant index fund buying if successful.
- Price Volatility Analysis: IBRX rose 1% in extended trading on Tuesday to close at $7.32, despite being down 3% so far this month; however, market optimism regarding its potential Russell 1000 inclusion suggests it could improve trading characteristics and attract more passive investors.
- Surge in Trading Volume: According to Stocktwits, IBRX's message volume surged by 349% over the past month, while retail sentiment shifted from 'bullish' to 'bearish', indicating heightened market attention and uncertainty surrounding the upcoming reconstitution.
- FDA Approval Boost: Last month, the FDA accepted ImmunityBio's application to expand Anktiva for bladder cancer treatment, with a decision expected on January 6, 2027, and clinical trial results showing 58.2% of patients disease-free after 12 months, further bolstering market confidence in IBRX.
See More
Federal Reserve's Policy Decision Draws Attention
- Fed Meeting Focus: Investors are closely watching Fed Chair Kevin Warsh's first meeting, where rates are expected to remain unchanged; however, his views on AI as a disinflationary force could spark market volatility, indicating a heightened focus on future monetary policy.
- Strong Market Performance: The Dow Jones Industrial Average reached a record high on Tuesday, propelling U.S. stock futures higher, with Nasdaq futures up 0.9%, reflecting optimistic sentiment towards the Fed's policy and potentially boosting investor confidence.
- Stock Movements: SpaceX shares surged approximately 50% from the $135 IPO price, briefly surpassing Microsoft and Amazon in market capitalization, highlighting strong market interest in emerging tech companies and their growth potential.
- Economic Data Watch: Investors are tracking retail sales data set to be released at 8:30 AM ET and the Fed's policy statement at 2:00 PM ET, with expectations that these figures will significantly impact market sentiment and investment decisions.
See More
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
GT Biopharma Advances Three Drug Candidates into Clinical Trials
- Clinical Trial Progress: GT Biopharma has advanced three TriKE® candidates into clinical trials, with GTB-5550's first patient dosing on May 14, 2026, marking the company's expansion from blood cancers to the broader solid tumor market, despite its market capitalization remaining below many peers.
- Drug Development Platform: The TriKE® platform developed by GT Biopharma aims to enhance the immune system's ability to target tumors by linking natural killer cells to specific cancer targets, demonstrating potential across various disease targets, particularly in hematologic malignancies and solid tumors.
- Clinical Trial Design: The clinical trial for GTB-3650 involves approximately 14 patients and employs a dose-escalation approach, with doses ranging from 1.25 µg/kg/day to 100 µg/kg/day, aimed at evaluating its efficacy in acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Valuation Gap: Despite significant clinical advancements, GT Biopharma's market valuation remains relatively low, creating a mismatch that attracts speculative interest; if any of its programs succeed, it could lead to substantial stock price appreciation.
See More
GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials
- Clinical Trial Progress: GT Biopharma has advanced three TriKE® candidates into clinical stages, with GTB-5550's first patient dosing on May 14, 2026, marking the company's expansion from blood cancers to the broader solid tumor market, indicating its potential in tumor immunotherapy.
- Drug Development Platform: GT Biopharma's TriKE® platform aims to enhance immune responses by linking natural killer cells to specific cancer targets, with current clinical projects including GTB-3650 for acute myeloid leukemia and GTB-5550 targeting B7-H3-marked solid tumors, showcasing a diversified treatment strategy.
- Valuation Gap: Despite advancing three candidates into clinical trials, GT Biopharma's market valuation remains below many peers, reflecting a tension between funding and clinical progress that attracts speculative interest; if any program succeeds, it could significantly enhance the company's value.
- Trial Design: The GTB-5550 trial employs a basket trial design, allowing patients with multiple tumor types to enroll under one protocol, which is an efficient approach for the company to quickly gather early signals and assess responses across different cancers while managing limited resources.
See More
Challenges and Opportunities in Neuro-Oncology
- Treatment Challenges: Despite significant advancements in cancer treatment over the past two decades, glioblastoma remains one of the deadliest cancers, with patients facing limited treatment options and poor long-term survival rates, highlighting a substantial unmet need in the field.
- NeOnc Technologies Progress: NeOnc Technologies is focused on developing therapies for central nervous system cancers, including NEO100 and NEO212, aimed at addressing significant unmet needs in neuro-oncology, attracting Wall Street attention and strong ratings from analysts.
- Investor Confidence: NeOnc's CEO has purchased over $500,000 in shares recently, with cumulative insider purchases approaching $1 million over the past year, demonstrating strong confidence in the company's future development.
- Industry Trends: As interest in novel drug delivery mechanisms grows, companies like Kazia Therapeutics and BioNTech are actively exploring treatment options for glioblastoma, indicating a rising investment and research momentum in this area.
See More
IBRX Poised for Russell 1000 Inclusion Amid Retail Trader Speculation
- Market Reconstitution Focus: Retail traders are closely watching Friday's Russell reconstitution, with IBRX potentially graduating from the Russell 2000 to the Russell 1000, as its current market cap of approximately $7.67 billion exceeds the $5.7 billion cutoff for 2026, which could trigger significant index fund buying if successful.
- Price Volatility Analysis: IBRX rose 1% in extended trading on Tuesday to close at $7.32, despite being down 3% so far this month; however, market optimism regarding its potential Russell 1000 inclusion suggests it could improve trading characteristics and attract more passive investors.
- Surge in Trading Volume: According to Stocktwits, IBRX's message volume surged by 349% over the past month, while retail sentiment shifted from 'bullish' to 'bearish', indicating heightened market attention and uncertainty surrounding the upcoming reconstitution.
- FDA Approval Boost: Last month, the FDA accepted ImmunityBio's application to expand Anktiva for bladder cancer treatment, with a decision expected on January 6, 2027, and clinical trial results showing 58.2% of patients disease-free after 12 months, further bolstering market confidence in IBRX.
See More
Federal Reserve's Policy Decision Draws Attention
- Fed Meeting Focus: Investors are closely watching Fed Chair Kevin Warsh's first meeting, where rates are expected to remain unchanged; however, his views on AI as a disinflationary force could spark market volatility, indicating a heightened focus on future monetary policy.
- Strong Market Performance: The Dow Jones Industrial Average reached a record high on Tuesday, propelling U.S. stock futures higher, with Nasdaq futures up 0.9%, reflecting optimistic sentiment towards the Fed's policy and potentially boosting investor confidence.
- Stock Movements: SpaceX shares surged approximately 50% from the $135 IPO price, briefly surpassing Microsoft and Amazon in market capitalization, highlighting strong market interest in emerging tech companies and their growth potential.
- Economic Data Watch: Investors are tracking retail sales data set to be released at 8:30 AM ET and the Fed's policy statement at 2:00 PM ET, with expectations that these figures will significantly impact market sentiment and investment decisions.
See More
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
GT Biopharma Advances Three Drug Candidates into Clinical Trials
- Clinical Trial Progress: GT Biopharma has advanced three TriKE® candidates into clinical trials, with GTB-5550's first patient dosing on May 14, 2026, marking the company's expansion from blood cancers to the broader solid tumor market, despite its market capitalization remaining below many peers.
- Drug Development Platform: The TriKE® platform developed by GT Biopharma aims to enhance the immune system's ability to target tumors by linking natural killer cells to specific cancer targets, demonstrating potential across various disease targets, particularly in hematologic malignancies and solid tumors.
- Clinical Trial Design: The clinical trial for GTB-3650 involves approximately 14 patients and employs a dose-escalation approach, with doses ranging from 1.25 µg/kg/day to 100 µg/kg/day, aimed at evaluating its efficacy in acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Valuation Gap: Despite significant clinical advancements, GT Biopharma's market valuation remains relatively low, creating a mismatch that attracts speculative interest; if any of its programs succeed, it could lead to substantial stock price appreciation.
See More
GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials
- Clinical Trial Progress: GT Biopharma has advanced three TriKE® candidates into clinical stages, with GTB-5550's first patient dosing on May 14, 2026, marking the company's expansion from blood cancers to the broader solid tumor market, indicating its potential in tumor immunotherapy.
- Drug Development Platform: GT Biopharma's TriKE® platform aims to enhance immune responses by linking natural killer cells to specific cancer targets, with current clinical projects including GTB-3650 for acute myeloid leukemia and GTB-5550 targeting B7-H3-marked solid tumors, showcasing a diversified treatment strategy.
- Valuation Gap: Despite advancing three candidates into clinical trials, GT Biopharma's market valuation remains below many peers, reflecting a tension between funding and clinical progress that attracts speculative interest; if any program succeeds, it could significantly enhance the company's value.
- Trial Design: The GTB-5550 trial employs a basket trial design, allowing patients with multiple tumor types to enroll under one protocol, which is an efficient approach for the company to quickly gather early signals and assess responses across different cancers while managing limited resources.
See More
Challenges and Opportunities in Neuro-Oncology
- Treatment Challenges: Despite significant advancements in cancer treatment over the past two decades, glioblastoma remains one of the deadliest cancers, with patients facing limited treatment options and poor long-term survival rates, highlighting a substantial unmet need in the field.
- NeOnc Technologies Progress: NeOnc Technologies is focused on developing therapies for central nervous system cancers, including NEO100 and NEO212, aimed at addressing significant unmet needs in neuro-oncology, attracting Wall Street attention and strong ratings from analysts.
- Investor Confidence: NeOnc's CEO has purchased over $500,000 in shares recently, with cumulative insider purchases approaching $1 million over the past year, demonstrating strong confidence in the company's future development.
- Industry Trends: As interest in novel drug delivery mechanisms grows, companies like Kazia Therapeutics and BioNTech are actively exploring treatment options for glioblastoma, indicating a rising investment and research momentum in this area.
See More
